Evotec SE (NASDAQ:EVO - Get Free Report)'s stock price gapped up prior to trading on Friday . The stock had previously closed at $3.78, but opened at $3.96. Evotec shares last traded at $3.92, with a volume of 21,718 shares trading hands.
Wall Street Analysts Forecast Growth
EVO has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft upgraded Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th. Royal Bank of Canada reissued an "outperform" rating on shares of Evotec in a research report on Thursday, May 15th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $5.93.
View Our Latest Research Report on EVO
Evotec Trading Up 1.8%
The firm has a 50-day moving average price of $3.80 and a two-hundred day moving average price of $4.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09.
Hedge Funds Weigh In On Evotec
Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new position in Evotec during the fourth quarter worth approximately $27,000. CSS LLC IL acquired a new stake in Evotec during the 4th quarter worth approximately $50,000. Bank of America Corp DE grew its stake in shares of Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after purchasing an additional 9,289 shares during the last quarter. Lighthouse Investment Partners LLC purchased a new position in shares of Evotec in the 4th quarter valued at approximately $166,000. Finally, ABC Arbitrage SA purchased a new stake in shares of Evotec during the first quarter worth approximately $260,000. 5.81% of the stock is currently owned by hedge funds and other institutional investors.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Recommended Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
